Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.40 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.40 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.40 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.40 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5777587 | 0.83 | SMN1; SMN2 (0.39) | — | |
| SCHEMBL31556506 | 0.82 | CES2 (0.43) | CES2CES1ORAI1ORAI2ORAI3 | |
| SCHEMBL1350898 | 0.81 | TNKS (0.40) | CES2CES1ORAI1ORAI2ORAI3 | |
| SCHEMBL13571355 | 0.80 | TSHR (0.48) | KIF11 | |
| SCHEMBL27780544 | 0.80 | SHBG (0.59) | — | |
| SCHEMBL19557869 | 0.80 | TRPV1 (0.46) | KIF11 | |
| SCHEMBL19987501 | 0.80 | CNR2 (0.42) | KIF11 | |
| SCHEMBL873051 | 0.77 | TAAR1 (0.54) | — | |
| SCHEMBL17223947 | 0.77 | CNR2 (0.49) | — | |
| Ammonia Solution, Strong SCHEMBL28211119 | 0.76 | TAAR1 (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11214540-B2 | Compositions for treating neurodegenerative diseases | COGNITION THERAPEUTICS, INC. (US) | 2022-01-04 | — | — | US | disclosed |
| US-20200299234-A1 | COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES | COGNITION THERAPEUTICS, INC. (US) | 2020-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11214540-B2 | Compositions for treating neurodegenerative diseases | NLN, GAP43, PSEN2 | CES2 2819/4885CES1 3329/4885ORAI1 2952/4885 |
| US-20200299234-A1 | COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES | GAP43, NLN, SNAP29 | CES2 2337/4885CES1 2969/4885ORAI1 2393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.